The legalization of marijuana has created tremendous opportunities for companies engaged in the cultivation, propagation, research and sale of cannabis. Companies that are developing medical applications of cannabis are already starting to show some gains in the market. Med-X’s Nature-Cide division has begun a decent on the marijuana industry with education from the Nature-Cide’s 18-Month IPM report.
With a market capitalization of $138.69 billion AbbVie Inc. pharmaceuticals is the pioneer in cannabis-base drugs.
The legalization of marijuana, particularly to exploit its medical use, has created tremendous opportunities for companies engaged in the cultivation, propagation, research and sale of cannabis.
Companies that are developing medical applications of cannabis are already starting to show some gains in the market and are expected to show upward movements. Below are the top marijuana stocks that are worth watching for.
1. AbbVie Inc. (ABBV)
With a market capitalization of $138.69 billion AbbVie Inc. pharmaceuticals is the pioneer in cannabis-based drugs. Its Marinol has been approved by the Food and Drug Administration and claims to be an effective treatment against nausea or vomiting for chemotherapy patients. Marinol is also used to help AIDS patients to regain their appetite.
Interestingly, Marinol is not AbbVie’s biggest revenue contributor nor is the drug the company’s flagship drug. However, ABBV has seen its profits rise over the last four years and its operating income steadily on the upward. The biggest drawback about AbbVie is it focused mainly in the U.S. markets. It would help if the company will try marketing its products outside of the U.S.
2. Scott’s Miracle-Gro (SMG)
This company gained popularity for its lawn and garden-care lines. Now the company has grown to $5.51 billion and has entered the marijuana boom with the development of products aimed at targeting cannabis growers. Scotts Miracle-Gro is also offering several pesticides for use in the cultivation of cannabis. After seeing its stock value dropped to nearly $83 per share from $97 in December 2016, Scotts Miracle-Gro’s share value is seeing a rebound recently.
Canada’s largest medical marijuana supplier “Canopy Growth” shares are experiencing a roller-coaster ride this year. Canopy Growth stocks jumped nearly 45% in mid-February this year before dropping sharply. In early June, Canopy Growth was down 25% year to date only to see a sudden rise. Up to early this month, Canopy Growth is up about 25.
But industry observers believe that company is on a bright spot given that Canada’s medical marijuana space is booming. The company has reported a 127% increase in sales year over year as of the end of the second quarter this year amounting to $15.9 million or up 8% from the first quarter.
reported sales in the quarter ending June 30, 2017, of $15.9 million — up 127% year over year and 8% from the previous quarter.
4. MedReleaf (LEAF)
The second largest medical-marijuana supplier in Canada in terms of revenue, MedReleaf only started to publicly trade in May, but has seen its value rise by more than 20% since late August. MedReleaf reported a 19% year-over-year rise in sales in the second quarter of this year. The company is looking for profits to jump higher from the sale of its cannabis oil products.
More importantly, the company is sold internationally. It has partnered with an Australian firm to cultivate and sell medical marijuana in the region. In July, MedReleaf has started to export its products in Brazil, while its German subsidiary, the MedReleaf Germany GmbH, is in its final stage of selling medical marijuana in that country.
A relative new player in the cannabis industry, Med-X, Inc. and its Nature-Cide brand, was born from licensed pest management company specializing in Integrated Pest Management (IPM) using unique blends of natural essential oils, that have been proven nationally in multiple commercial settings.
Med-X, is the exclusive distributor of the Nature-Cide line of products for the marijuana industry. As a research, development and education company, its personnel is considered industry leaders at the forefront of “Minimum Risk Pesticide” usage, in many aspects of pest management. In March 2017 Med-X, Inc released The Nature-Cide 18-Month Integrated Pest Management for Cannabis Cultivation Report.
Med-X’s Nature-Cide division has begun a decent on the marijuana industry with education from the Nature-Cide’s 18-Month IPM report, that gives Pest Control operators the ability to successfully integrate marijuana cultivation facility pest control protocols, into an everyday routine. Med-X’s Nature-Cide division will position Pest Control companies in multiple states beginning in Colorado with Madero Pest Control in Pueblo CO. Madero Pest Control services a variety of commercial (Including Cannabis Cultivation) and residential clients throughout the city of Pueblo. In mid-2015, Madero Pest Control began to see a demand coming from cannabis cultivators and medical marijuana dispensaries in the immediate area.
The Nature-Cide IPM protocol seems to join the marijuana cultivation community with pest control professionals in a seemingly imminent marriage, and solid reasoning why in most other agricultural settings, licensed pest control applicators are deployed to keep mainstream agricultural farmers, 100% compliant with pest control applications.